Christina Schellenbacher - Infectious Diseases

Author Information

Christina Schellenbacher is affiliated with the Laboratory of Viral Oncology (LVO) within the Division of Immunology, Allergy and Infectious Diseases (DIAID) at the Department of Dermatology, Medical University of Vienna, Austria. Her research focus is primarily in the field of viral oncology, with a specific emphasis on human papillomavirus (HPV) and the development of vaccines aimed at preventing HPV-associated diseases.

Research Contributions

Christina Schellenbacher has significantly contributed to the field of HPV research, particularly in the development of virus-like particle (VLP) vaccines. Her work includes the exploration of chimeric VLP vaccines for HPV16 and the incorporation of RG1 epitopes to enhance cross-protection. Her research spans the development of L2-based HPV vaccines and the examination of their potential to induce neutralizing antibodies in oral mucosal fluids. The impact of her work is evident in the advancements in pre-clinical models and vaccine production for the prevention of HPV-associated cancers, as well as in developing vaccines for non-human papillomavirus types.

Aliases

Christina Schellenbacher is also known by the aliases C Schellenbacher and C. Schellenbacher in various publications.

Publication and Citation Metrics

Metric	Value
Total Citations	721
h-index	13
Total Papers	23

Publications:

Abstract LB-200: A cGMP-grade chimeric papillomavirus candidate vaccine (HPV16 RG1-VLP) confers long term cross-protection compared to a nonavalent hpv vaccine in a pre-clinical papillomavirus animal model

DOI: 10.1158/1538-7445.AM2019-LB-200

Year: 2019

Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity.

DOI: 10.1016/j.vaccine.2019.05.011

Year: 2019

Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV)

DOI: 10.1371/journal.pone.0169533

Year: 2017

Developments in L2-based human papillomavirus (HPV) vaccines.

DOI: 10.1016/j.virusres.2016.11.020

Year: 2017

Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids

DOI: 10.1038/bjc.2015.462

Year: 2016

Abstract 2367: cGMP production of a chimeric virus-like particle vaccine for prevention of HPV-associated cancers

DOI: 10.1158/1538-7445.AM2016-2367

Year: 2016

426 cGMP production of a chimeric virus-like particle vaccine (RG1-VLP) for prevention of HPV-associated cancers

DOI: 10.1016/J.JID.2016.06.446

Year: 2016

Progress and prospects for L 2-based human papillomavirus vaccines

DOI:

Year: 2016

Progress and prospects for L2-based human papillomavirus vaccines

DOI: 10.1586/14760584.2016.1157479

Year: 2016

Establishment of an in vitro equine papillomavirus type 2 (EcPV2) neutralization assay and a VLP-based vaccine for protection of equids against EcPV2-associated genital tumors.

DOI: 10.1016/j.virol.2015.08.016

Year: 2015

How is Gene Therapy Applied in Infectious Diseases?

How Do Pathogens Exploit Host Metabolic Pathways?

How Can We Improve Global Health Infrastructure to Combat Infectious Diseases?

How Are Bacterial Infections Diagnosed?

Why is Fatty Acid Biosynthesis a Therapeutic Target?

How Do Human Activities Amplify These Effects?

What are Antimicrobials?

How Do Pathogens Evade Folate Inhibition?

How does it spread?

What are Pediatric Infectious Diseases?

Partnered Content Networks

Relevant Topics